Know More about Scott Rocklage – Managing Partner at 5AM Ventures

Scott M. Rocklage joined 5 AM Ventures as a Venture Partner in 2003. In 2004, he became a Managing Partner. The Ph.D. holder boasts of more than three decades of management experience in the healthcare industry. One of the strategic leadership roles he has held includes the one that led to the FDA approval of three New Drug Applications in the United States – Omniscan, Teslascan, and Cubicin. Scott M. Rocklage has also entered multiple drug candidates into various clinical trials. He has worked as the CEO and chairman of Cubist Pharmaceuticals, as well as the CEO and president of Nycomed Salutar. He has also held different positions in research and development both at Catalytica and Salutar.

During an interview with Ideamensch, Scott Rocklage was asked where the idea of 5 AM venture came from. In his response, he suggested that the idea and the name of the company originated from the fact that the firm is involved in the business of company formation that is seen as an early stage. When asked to describe his typical day, Rocklage said that he does not have one. The nature of his activities usually varies from one day to the other. For instance, he spends some days studying new areas of life in matters science, and in other days, he spends working with the management team of the company’s portfolio. Other days, he is preparing or attending board meetings. Rocklage does not seem to have a routine as far his working hours are concerned and resume him.

To bring ideas to life, Scott M. Rocklage works with entrepreneurs – physicians, scientists or business executives – to help them convert their ideas into potential medicines capable of treating unmet medical needs. The habits that have increased his productivity as an entrepreneur include proper time management, organization, and the ability to prioritize and Scott’s lacrosse camp.

Just like the majority of high profile entrepreneurs, Rocklage has one trend that excites him. For him, it is the huge growth witnessed in the ability to target particular genotypes or mutations to treat cancer in unique ways. As a result, many lives have been saved and extended, and more developments will be seen in the near future.